These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16982785)

  • 21. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
    Hart D; Weinstein MP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
    Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of antimicrobial activity of ciprofloxacin by Pelargonium graveolens essential oil against selected uropathogens.
    Malik T; Singh P; Pant S; Chauhan N; Lohani H
    Phytother Res; 2011 Aug; 25(8):1225-8. PubMed ID: 21618302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
    Ponte C; Gracia M; Giménez MJ; Aguilar L; Maín CM; Carpintero Y; Huelves L; Carcas A; del Prado G; Soriano F
    Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
    Washington CB; Hou SY; Campanella C; Hughes N; Brown S; Berner B
    J Clin Pharmacol; 2005 Nov; 45(11):1236-44. PubMed ID: 16239356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antibacterial activity of ciprofloxacin in the urine during four days after a single 500 mg and 750 mg oral dose].
    Guibert J; Kitzis MD; Acar JF
    Pathol Biol (Paris); 1994 Jun; 42(6):587-92. PubMed ID: 7854859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial.
    Cantor LB; WuDunn D; Yung CW; Valluri S; Catoira YP; Hoop JS; Morgan LS
    Br J Ophthalmol; 2008 Mar; 92(3):345-7. PubMed ID: 18211932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary excretion of ciprofloxacin after administration of extended release tablets in healthy volunteers. Swellable drug-polyelectrolyte matrix versus bilayer tablets.
    Guzmán ML; Romañuk CB; Sanchez MF; Luciani Giacobbe LC; Alarcón-Ramirez LP; Battistini FD; Alovero FL; Jimenez-Kairuz AF; Manzo RH; Olivera ME
    Drug Deliv Transl Res; 2018 Feb; 8(1):123-131. PubMed ID: 29159694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
    Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
    [No Abstract]   [Full Text] [Related]  

  • 36. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
    Bosso JA; Mauldin PD
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2106-12. PubMed ID: 16723572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
    Stein GE; Schooley S
    Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination.
    Bulitta JB; Kinzig M; Naber CK; Wagenlehner FM; Sauber C; Landersdorfer CB; Sörgel F; Naber KG
    Chemotherapy; 2011; 57(5):402-16. PubMed ID: 22024700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
    Schaeffer AJ; Wu SC; Tennenberg AM; Kahn JB
    J Urol; 2005 Jul; 174(1):161-4. PubMed ID: 15947609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.